Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: ECYT
- CUSIP: 29269A10
- Previous Close: $2.07
- 50 Day Moving Average: $2.26
- 200 Day Moving Average: $2.77
- 52-Week Range: $42,268,000.00 - $1.98
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.67
- P/E Growth: 0.00
- Market Cap: $86.23M
- Outstanding Shares: 42,268,000
- Beta: 1.84
- Net Margins: -57,108.57%
- Return on Equity: -25.17%
- Return on Assets: -24.29%
Companies Related to Endocyte:
- Current Ratio: 32.65%
- Quick Ratio: 32.65%
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?
3 equities research analysts have issued 1 year price objectives for Endocyte's shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Endocyte's stock price to reach $7.50 in the next twelve months.
When will Endocyte announce their earnings?
Endocyte is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns Endocyte stock?
Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.24%), Pinnacle Associates Ltd. (1.94%), State Street Corp (1.47%), Highland Capital Management LP (1.09%), Oxford Asset Management (0.50%) and Employees Retirement System of Texas (0.32%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low.
Who sold Endocyte stock? Who is selling Endocyte stock?
Endocyte's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Pinnacle Associates Ltd. and Highland Capital Management LP.
Who bought Endocyte stock? Who is buying Endocyte stock?
Endocyte's stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management, Two Sigma Investments LP, FMR LLC and State Street Corp. Company insiders that have bought Endocyte stock in the last two years include Fred A Middleton and Philip S Low.
How do I buy Endocyte stock?
Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Endocyte stock cost?
One share of Endocyte stock can currently be purchased for approximately $2.04.